The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease in more than a decade.

Merck & Co. shares were climbing 3.1% in afternoon trading after the pharmaceutical giant announced a $10 billion deal to acquire respiratory-disease specialist Verona Pharma PLC. The deal adds Verona ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

The global dysmenorrhea treatment market, valued at approximately USD 5,937.8 million in 2022, is projected to reach USD 6,324.5 million in 2023 and USD 13,106.5 million by 2032, exhibiting a CAGR of ...

The Benzalkonium Chloride Market is expected to grow at a CAGR of 8.6% during the forecast period 2024-2031. The Benzalkonium ...

The Global Mycoplasma Testing Market is expected to witness a high growth rate of 11% from 2022 to 2027. Growing R&D ...

Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck & Co's significant trades, within a strike price range of $40.0 to $110.0, over the past month.

Merck Animal Health To Invest $895M To Expand Production, R&D In Kansas A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...